Evident Vascular, Inc. Company Profile

Background

Evident Vascular, Inc., founded in 2021 and headquartered in San Jose, California, is a medical technology company specializing in the development of advanced intravascular ultrasound (IVUS) platforms. The company's mission is to improve the lives of patients suffering from vascular disease through innovative imaging solutions. By integrating artificial intelligence (AI) into IVUS technology, Evident Vascular aims to enhance vascular imaging, streamline clinical workflows, and improve patient outcomes.

Key Strategic Focus

Evident Vascular's strategic focus centers on:

Core Objectives: Developing a next-generation IVUS platform that leverages AI to provide superior image interpretation and streamlined workflows, thereby expanding IVUS adoption in peripheral and coronary interventions.

Areas of Specialization: Concentrating on peripheral vascular interventions with plans to extend capabilities to coronary procedures.

Key Technologies: Utilizing AI algorithms to automatically identify and segment key vascular structures, offering clinicians real-time insights and guidance.

Target Markets: Addressing the growing need for advanced vascular imaging solutions in the United States and potentially expanding to international markets.

Financials and Funding

Evident Vascular has secured significant funding to support its development initiatives:

Series A Financing: In October 2023, the company raised $35 million from Vensana Capital to develop its AI-powered IVUS platform.

Series B Financing: In March 2025, additional funding was secured from new investors, including Shangbay Capital and two undisclosed multinational strategics, alongside Vensana Capital. This funding aims to accelerate the development of the IVUS technology and support FDA 510(k) clearance ahead of the U.S. market launch.

Pipeline Development

Evident Vascular is actively developing its flagship product:

Evident Vascular™ Guidance System: An AI-powered IVUS platform designed to enhance image interpretation and streamline workflows for peripheral vascular interventions, with future capabilities for coronary procedures. The company is progressing towards FDA 510(k) clearance, with plans for a U.S. market launch upon approval.

Technological Platform and Innovation

Evident Vascular's innovation is characterized by:

Proprietary Technologies: Development of an advanced IVUS system that integrates AI to improve image quality and interpretation.

Scientific Methodologies: Application of AI algorithms to automatically identify and segment vascular structures, providing real-time insights to clinicians.

Leadership Team

Evident Vascular's leadership comprises experienced professionals:

Howard Rosen: Co-Founder & Chief Executive Officer. Brings extensive experience in medical device innovation and leadership.

Patrick Phillips, PhD: Co-Founder & Chief Technology Officer. Specializes in catheter-based ultrasound technologies and diagnostic imaging.

Danielo Piazza: Co-Founder & Chief Product Officer. Expertise in product development and image-guided therapy.

Leadership Changes

In January 2025, Scott R. Ward, with over 40 years of leadership in healthcare and medical technology, joined the Board of Directors, bringing valuable experience to support the company's growth and strategic initiatives.

Competitor Profile

Market Insights and Dynamics

The IVUS market is experiencing growth due to increasing peripheral vascular interventions and the need for advanced imaging solutions. The integration of AI into IVUS platforms is a significant trend, aiming to enhance image quality and clinical decision-making.

Competitor Analysis

Key competitors in the IVUS market include:

LeMaitre Vascular: Established in 1986, LeMaitre Vascular provides devices and implants for vascular conditions, including peripheral vascular disease. The company has a global presence, selling directly to hospitals in 25 countries and through distributors in over 70 countries.

Strategic Collaborations and Partnerships

Evident Vascular has established significant partnerships to bolster its market position:

Vensana Capital: Lead investor in Series A financing, providing financial support and strategic guidance.

Shangbay Capital: Participated in Series B financing, contributing to the acceleration of product development and market entry.

Operational Insights

Evident Vascular's strategic considerations include:

Market Position: Aiming to establish a strong foothold in the IVUS market by offering an AI-powered platform tailored for peripheral vascular interventions.

Competitive Advantages: Differentiating through the integration of AI to enhance image interpretation and workflow efficiency, addressing limitations of legacy IVUS systems.

Strategic Opportunities and Future Directions

Evident Vascular's roadmap includes:

FDA Clearance: Pursuing 510(k) clearance to facilitate U.S. market entry.

Product Expansion: Extending the IVUS platform's capabilities to coronary interventions.

Market Penetration: Leveraging partnerships and technological innovations to increase IVUS adoption and improve patient outcomes.

Contact Information

For more information, visit Evident Vascular's official website.

Follow Evident Vascular on LinkedIn.

Note: This profile is based on information available as of July 11, 2025.